Name | BAY 87-2243 |
Description | BAY 87-2243 is a potent and selective inhibitor of hypoxia-inducible factor-1 (HIF-1). |
Cell Research | To evaluate the cytotoxicity of BAY 87-2243, 2.000 cells of the respective cell lines are seeded in 96-well plates and cultured in the appropriate growth medium containing 10% FCS. BAY 87-2243 at various concentrations is added at 24 h after seeding for additional 48 h and cell viability is determined using Cell Titer Glow Assay.(Only for Reference) |
In vitro | BAY87-2243 (administered orally at 4 mg/kg) reduced tumor weight, HIF-1α protein, and HIF-1 target gene expression levels in an H460 xenograft mouse model. |
In vivo | In hypoxic lung cancer H460 cells, BAY 87-2243 inhibits the expression of HIF target genes and suppresses the accumulation of HIF-1α protein. It impairs cell proliferation by interfering with mitochondrial function under glucose consumption. Additionally, BAY 87-2243 inhibits the reporter gene activity of HIF-1 and the expression of CA9 protein, with IC50 values of 0.7 nM and 2 nM, respectively. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 52.55 mg/mL (100 mM), Sonication and heating are recommended.
|
Keywords | Ferroptosis | inhibit | BAY 87-2243 | HIFs | HIF-PH | HIF/HIF Prolyl-Hydroxylase | Inhibitor | BAY 872243 | Hypoxia-inducible factors | BAY 87 2243 |
Inhibitors Related | TBHQ | Acetylcysteine | Butylated hydroxytoluene | α-Vitamin E | Sorafenib | Curcumin | Glucosamine | Hydroxycitric acid tripotassium hydrate | Artemisinin | L-Cystine | L-Glutamic acid monosodium salt | Coenzyme Q10 |
Related Compound Libraries | Bioactive Compound Library | HIF-1 Signaling Pathway Compound Library | Anti-Cancer Metabolism Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |